# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY ONLY TEMPLATE

Modification of a previously cleared Acetaminophen assay (k081938), including a change in

A. 510(k) Number: k180835   
B. Purpose for Submission: reagent formulation.   
C. Measurand: Acetaminophen   
D. Type of Test: Quantitative colorimetric assay   
E. Applicant: Sekisui Diagnostics PEI Inc.   
F. Proprietary and Established Names: SEKURE Acetaminophen L3K Assay   
G. Regulatory Information:

<table><tr><td rowspan=1 colspan=1>ProductCode</td><td rowspan=1 colspan=1>Classification</td><td rowspan=1 colspan=1>Regulation Section</td><td rowspan=1 colspan=1>Panel</td></tr><tr><td rowspan=1 colspan=1>LDP</td><td rowspan=1 colspan=1>I</td><td rowspan=1 colspan=1>21 CFR 862.3030, Acetaminophen test]system</td><td rowspan=1 colspan=1>91- Toxicology</td></tr></table>

# H. Intended Use:

1. Intended use(s): See Indications for use below.

2. Indication(s) for use:

For the in vitro quantitative measurement of acetaminophen in serum, lithium heparin plasma and sodium heparin plasma. Measurement of acetaminophen is used in the diagnosis and treatment of acetaminophen overdose toxicity.

3. Special conditions for use statement(s): For prescription use only

4. Special instrument requirements: Roche Hitachi 717 chemistry analyzer

# I. Device Description:

The SEKURE Acetaminophen L3K assay consists of two reagents, an enzyme reagent and a color reagent, and a calibrator.

Acetaminophen Enzyme Reagent (R1): A solution containing buffer $\mathrm { \Phi _ { p H 8 . 6 } }$ at $2 5 ^ { \circ } \mathrm { C } )$ , 0.3 mmol/L MnCl24H2O, $\geq 0 . 9$ KU/L Acyl Amidohydrolase (microbial), 50 $\mathrm { m g / L }$ sodium azide.   
Acetaminophen Color Reagent (R2): A solution containing $0 . 1 \mathrm { m o l / L }$ sodium carbonate buffer $\mathrm { p H } 1 1 . 5$ at $2 5 ^ { \circ } \mathrm { C }$ ), 31 mmol/L 2,5-dimethylphenol, stabilizer, preservative.   
Acetaminophen Calibrator: $1 \mathrm { ~ x ~ } 5 \mathrm { ~ m L }$ of a solution containing buffer $\mathrm { ( p H } 5 . 2$ at $2 5 ^ { \circ } \mathrm { C }$ ), $1 5 1 ~ \mu \mathrm { g / m L }$ ( $1 0 0 0 \mu \mathrm { m o l / L } )$ acetaminophen, preservatives.

# J. Substantial Equivalence Information:

1. Predicate device name(s) and 510(k) numbers: Acetaminophen L3K Assay, k081938

2. Comparison with predicate:

<table><tr><td colspan="3" rowspan="1">Similarities</td></tr><tr><td colspan="1" rowspan="1">Feature</td><td colspan="1" rowspan="1">Predicate Device (k081938):Acetaminophen L3K Assay</td><td colspan="1" rowspan="1">Candidate Device: SEKUREAcetaminophen L3K AssayAssay</td></tr><tr><td colspan="1" rowspan="1">Intended Use</td><td colspan="1" rowspan="1">Intended for the in vitroquantitative measurement ofacetaminophen in serum andplasma. Measurement ofacetaminophen is used in thediagnosis and treatment ofacetaminophen overdose toxicity.</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Test Principle</td><td colspan="1" rowspan="1">Enzymatic and Spectrophotometric</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Platform</td><td colspan="1" rowspan="1">Hitachi 717</td><td colspan="1" rowspan="1">Same</td></tr></table>

<table><tr><td rowspan=1 colspan=3>Differences</td></tr><tr><td rowspan=1 colspan=1>Feature</td><td rowspan=1 colspan=1>Predicate Device (k081938):Acetaminophen L3K Assay</td><td rowspan=1 colspan=1>Candidate Device: SEKUREAcetaminophen L3K AssayAssay</td></tr><tr><td rowspan=1 colspan=1>Sample Types</td><td rowspan=1 colspan=1>Serum and lithium heparin plasma</td><td rowspan=1 colspan=1>Serum, lithium heparin plasma andsodium heparin plasma</td></tr><tr><td rowspan=1 colspan=1>Measuringinterval</td><td rowspan=1 colspan=1>4 to 2500 µmol/L (0.6 to 377.5μg/mL)</td><td rowspan=1 colspan=1>115 to 2500 µmol/L (17.4 to 377.5μg/mL)</td></tr></table>

# K. Standard/Guidance Document Referenced (if applicable):

· CLSI EP05-A3- Evaluation of Precision Performance of Quantitative Measurement Methods   
· CLSI EP06-A- Evaluation of the Linearity of Quantitative Measurement Procedures: A Statistical Approach   
C CLSI EP07-A2- Interference Testing in Clinical Chemistry   
· CLSI EP17-A2- Evaluation of Detection Capability for Clinical Laboratory Measurement Procedures   
· CLSI EP09-A3- Method Comparison and Bias Estimation Using Patient Samples; Approved Guideline-Second Edition   
· CLSI EP25-A- Evaluation of Stability of In Vitro Diagnostic Reagents

# L. Test Principle:

The enzyme, acyl amidohydrolase, cleaves the amide bond of the acetaminophen molecule, leaving p-aminophenol and acetate. The p-aminophenol is coupled with 2,5-dimethylphenol in the presence of manganese ions to form a colored compound, 4-(4-iminophenol)-2,5- dimethylcyclohexadiene-1-one. The increased absorbance at $6 0 5 \mathrm { n m }$ due to the formation of 4-(4-iminophenol)-2,5-dimethylcyclohexadiene-1-one is directly proportional to the concentration of acetaminophen in the sample.

# M. Performance Characteristics (if/when applicable):

All performance studies were conducted with the Roche Hitachi 717 clinical chemistry analyzer.

1. Analytical performance:

# a. Precision/Reproducibility:

A precision study was performed using two unaltered patient serum samples, two spiked patient serum samples and three levels of controls, assayed in duplicate, twice a day, for 20 days, with daily calibration. Each sample was evaluated using six lots of Acetaminophen L3K Assay.

Repeatability:   

<table><tr><td rowspan=2 colspan=1>Lot</td><td rowspan=2 colspan=1>Sample</td><td rowspan=2 colspan=1>N</td><td rowspan=2 colspan=1>MeanAcetaminophen(μmol/L)</td><td rowspan=1 colspan=2>Repeatability</td><td rowspan=1 colspan=2>WithinLaboratory</td></tr><tr><td rowspan=1 colspan=1>SD(μmol/L)</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD(μmol/L)</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=3 colspan=1>1</td><td rowspan=1 colspan=1>Control 1</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>68</td><td rowspan=1 colspan=1>1.8</td><td rowspan=1 colspan=1>2.7</td><td rowspan=1 colspan=1>2.5</td><td rowspan=1 colspan=1>3.8</td></tr><tr><td rowspan=1 colspan=1>Control 2</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>238</td><td rowspan=1 colspan=1>4.4</td><td rowspan=1 colspan=1>1.9</td><td rowspan=1 colspan=1>6.1</td><td rowspan=1 colspan=1>2.6</td></tr><tr><td rowspan=1 colspan=1>Control 3</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>764</td><td rowspan=1 colspan=1>13.4</td><td rowspan=1 colspan=1>1.8</td><td rowspan=1 colspan=1>14.3</td><td rowspan=1 colspan=1>1.9</td></tr><tr><td rowspan=4 colspan=1>2</td><td rowspan=1 colspan=1>Unaltered P1</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>170.3</td><td rowspan=1 colspan=1>2.1</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>2.4</td><td rowspan=1 colspan=1>1.4</td></tr><tr><td rowspan=1 colspan=1>Unaltered P2</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>195.5</td><td rowspan=1 colspan=1>2.4</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>2.6</td><td rowspan=1 colspan=1>1.4</td></tr><tr><td rowspan=1 colspan=1>Spiked 1</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>1295.9</td><td rowspan=1 colspan=1>11.5</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>19.7</td><td rowspan=1 colspan=1>1.5</td></tr><tr><td rowspan=1 colspan=1>Spiked 2</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>2278.6</td><td rowspan=1 colspan=1>17.3</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>51.0</td><td rowspan=1 colspan=1>2.2</td></tr><tr><td rowspan=3 colspan=1>3</td><td rowspan=1 colspan=1>Control 1</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>68</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>1.7</td><td rowspan=1 colspan=1>2.4</td><td rowspan=1 colspan=1>3.5</td></tr><tr><td rowspan=1 colspan=1>Control 2</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>238</td><td rowspan=1 colspan=1>3.9</td><td rowspan=1 colspan=1>1.7</td><td rowspan=1 colspan=1>5.8</td><td rowspan=1 colspan=1>2.4</td></tr><tr><td rowspan=1 colspan=1>Control 3</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>764</td><td rowspan=1 colspan=1>14.2</td><td rowspan=1 colspan=1>1.9</td><td rowspan=1 colspan=1>14.2</td><td rowspan=1 colspan=1>1.9</td></tr><tr><td rowspan=4 colspan=1>4</td><td rowspan=1 colspan=1>Unaltered P1</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>169.5</td><td rowspan=1 colspan=1>1.5</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>2.1</td><td rowspan=1 colspan=1>1.2</td></tr><tr><td rowspan=1 colspan=1>Unaltered P2</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>195.4</td><td rowspan=1 colspan=1>2.6</td><td rowspan=1 colspan=1>1.3</td><td rowspan=1 colspan=1>2.6</td><td rowspan=1 colspan=1>1.3</td></tr><tr><td rowspan=1 colspan=1>Spiked 1</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>1294.3</td><td rowspan=1 colspan=1>12.8</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>21.4</td><td rowspan=1 colspan=1>1.7</td></tr><tr><td rowspan=1 colspan=1>Spiked 2</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>2281.5</td><td rowspan=1 colspan=1>15.9</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>52.3</td><td rowspan=1 colspan=1>2.3</td></tr><tr><td rowspan=3 colspan=1>5</td><td rowspan=1 colspan=1>Control 1</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>68</td><td rowspan=1 colspan=1>1.4</td><td rowspan=1 colspan=1>2.0</td><td rowspan=1 colspan=1>2.4</td><td rowspan=1 colspan=1>3.5</td></tr><tr><td rowspan=1 colspan=1>Control 2</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>238</td><td rowspan=1 colspan=1>4.0</td><td rowspan=1 colspan=1>1.6</td><td rowspan=1 colspan=1>5.8</td><td rowspan=1 colspan=1>2.4</td></tr><tr><td rowspan=1 colspan=1>Control 3</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>764</td><td rowspan=1 colspan=1>13.6</td><td rowspan=1 colspan=1>1.7</td><td rowspan=1 colspan=1>14.2</td><td rowspan=1 colspan=1>1.8</td></tr><tr><td rowspan=4 colspan=1>6</td><td rowspan=1 colspan=1>Unaltered P1</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>175.0</td><td rowspan=1 colspan=1>1.6</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>2.0</td><td rowspan=1 colspan=1>1.2</td></tr><tr><td rowspan=1 colspan=1>Unaltered P2</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>202.0</td><td rowspan=1 colspan=1>2.7</td><td rowspan=1 colspan=1>1.3</td><td rowspan=1 colspan=1>3.0</td><td rowspan=1 colspan=1>1.5</td></tr><tr><td rowspan=1 colspan=1>Spiked 1</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>1339.3</td><td rowspan=1 colspan=1>13.8</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>22.5</td><td rowspan=1 colspan=1>1.7</td></tr><tr><td rowspan=1 colspan=1>Spiked 2</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>2357.9</td><td rowspan=1 colspan=1>17.5</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>50.0</td><td rowspan=1 colspan=1>2.1</td></tr></table>

# $b$ . Linearity/assay reportable range:

Linearity was conducted in a study using three lots of SEKURE Acetaminophen L3K reagent and two lots of calibrator. Nine samples from 100 to $2 7 0 0 ~ \mathrm { \mu m o l / L }$ acetaminophen were prepared. A high concentration stock was prepared from a stock acetaminophen standard of USP acetaminophen in pooled acetaminophen-free human serum. The high concentration stock was then diluted with an acetaminophen free sample to generate seven linearity samples. Expected concentrations were calculated based on the known value of the USP standard material values and the dilution factors. Samples were analyzed in quadruplicate. The mean and deviation of the

measured mean from theoretical values were calculated.

<table><tr><td rowspan=2 colspan=1>ExpectedAcetaminophen(μmol/L)</td><td rowspan=1 colspan=2>Lot 1</td><td rowspan=1 colspan=2>Lot 2</td><td rowspan=1 colspan=2>Lot 3</td></tr><tr><td rowspan=1 colspan=1>Observed(μmol/L)</td><td rowspan=1 colspan=1>Deviation(%)</td><td rowspan=1 colspan=1>ObservedDeviation(μmol/L)</td><td rowspan=1 colspan=1>ObservedDeviation(%)</td><td rowspan=1 colspan=1>ObservedDeviation(μmol/L)</td><td rowspan=1 colspan=1>ObservedDeviation(%)</td></tr><tr><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>98.8</td><td rowspan=1 colspan=1>-1.2%</td><td rowspan=1 colspan=1>99.3</td><td rowspan=1 colspan=1>-0.7%</td><td rowspan=1 colspan=1>101.3</td><td rowspan=1 colspan=1>1.3%</td></tr><tr><td rowspan=1 colspan=1>115</td><td rowspan=1 colspan=1>116.3</td><td rowspan=1 colspan=1>1.1%</td><td rowspan=1 colspan=1>115.5</td><td rowspan=1 colspan=1>0.4%</td><td rowspan=1 colspan=1>118.5</td><td rowspan=1 colspan=1>3.0%</td></tr><tr><td rowspan=1 colspan=1>125</td><td rowspan=1 colspan=1>125.3</td><td rowspan=1 colspan=1>0.2%</td><td rowspan=1 colspan=1>124.5</td><td rowspan=1 colspan=1>-0.4%</td><td rowspan=1 colspan=1>128.8</td><td rowspan=1 colspan=1>3.0%</td></tr><tr><td rowspan=1 colspan=1>250</td><td rowspan=1 colspan=1>251.0</td><td rowspan=1 colspan=1>0.4%</td><td rowspan=1 colspan=1>251.5</td><td rowspan=1 colspan=1>0.6%</td><td rowspan=1 colspan=1>260.3</td><td rowspan=1 colspan=1>4.1%</td></tr><tr><td rowspan=1 colspan=1>500</td><td rowspan=1 colspan=1>489.5</td><td rowspan=1 colspan=1>-2.1%</td><td rowspan=1 colspan=1>493.0</td><td rowspan=1 colspan=1>-1.4%</td><td rowspan=1 colspan=1>509.8</td><td rowspan=1 colspan=1>2.0%</td></tr><tr><td rowspan=1 colspan=1>1000</td><td rowspan=1 colspan=1>1015.8</td><td rowspan=1 colspan=1>1.6%</td><td rowspan=1 colspan=1>1022.8</td><td rowspan=1 colspan=1>2.3%</td><td rowspan=1 colspan=1>1048.8</td><td rowspan=1 colspan=1>4.9%</td></tr><tr><td rowspan=1 colspan=1>2000</td><td rowspan=1 colspan=1>2018</td><td rowspan=1 colspan=1>0.9%</td><td rowspan=1 colspan=1>2020.0</td><td rowspan=1 colspan=1>1.0%</td><td rowspan=1 colspan=1>2079.5</td><td rowspan=1 colspan=1>4.0%</td></tr><tr><td rowspan=1 colspan=1>2500</td><td rowspan=1 colspan=1>2515</td><td rowspan=1 colspan=1>0.6%</td><td rowspan=1 colspan=1>2501.3</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>2587.3</td><td rowspan=1 colspan=1>3.5%</td></tr><tr><td rowspan=1 colspan=1>2700</td><td rowspan=1 colspan=1>2690.3</td><td rowspan=1 colspan=1>-0.4%</td><td rowspan=1 colspan=1>2686.5</td><td rowspan=1 colspan=1>-0.5%</td><td rowspan=1 colspan=1>2784.5</td><td rowspan=1 colspan=1>3.1%</td></tr></table>

The linearity data met acceptance criteria and support a measuring range from 115 to $2 5 0 0 \ \mathrm { \mu m o l / L }$ (17.4 to $3 7 7 . 5 \mu \mathrm { g / m L }$ ).

c. Traceability, Stability, Expected values (controls, calibrators, or methods):

The SEKURE Acetaminophen Calibrator is traceable to USP grade reference acetaminophen material. Stability protocol and results are reviewed and found acceptable. Stability testing supports a shelf life of 12 months.

# d. Detection limit:

Limit of Blank (LoB): LoB was evaluated according to CLSI EP17-A2 using three lots of SEKURE Acetaminophen L3K reagent on the Hitachi 717. Five blank samples were assayed over three operating days for a total of 60 replicates per sample. For each reagent lot, the LoB results were ranked from lowest to highest concentration, and the LoB was estimated to be the result equivalent to the concentration at the 95th percentile. The LoB was determined to be $1 . 0 \ \mathrm { \textmu m o l { L } }$ .

Limit of Detection (LoD): Five low level samples were evaluated using three lots of reagents over three operating days for a total of 60 replicates per sample. The LoD was calculated for each reagent lot by $\mathrm { L o D } = \mathrm { L o B } + \mathrm { C } _ { \mathrm { p } } \mathrm { S D } _ { \mathrm { L } }$ . This study yielded a LoD of $2 . 4 \mu \mathrm { m o l / L }$ .

Limit of quantitation (LoQ): A set of six low-level samples was measured using three lots of reagents over five runs across three operating days for a total of 40 replicates per sample. The LoQ was calculated based on $\%$ total error is $< 2 5 \%$ . The LoQ was determined to be $8 ~ \mu \mathrm { m o l / L }$ .

# e. Analytical specificity:

# i. Interference from endogenous substances/cross reactants

Interference studies were performed in accordance to CLSI EP07-A2. Four acetaminophen serum pools prepared from USP acetaminophen dissolved in patient serum pool $( 3 3 \mathrm { \mu m o l / L }$ , $1 0 0 \mu \mathrm { m o l / L }$ , $1 9 9 \mu \mathrm { m o l / L }$ and $9 0 0 \mu \mathrm { m o l / L } )$ were evaluated. Testing was conducted using three lots of Acetaminophen reagent and two lots of calibrator on the Hitachi 717. The potential interferents were added individually to aliquots of the serum specimen pools. Control samples contained corresponding concentrations of acetaminophen without potential interferents. Significant interference was evaluated using a significance criterion of greater than $\pm 1 0 \%$ or 8 $\mu \mathrm { m o l / L }$ from control. The highest concentrations of each substance that did not show significant interference with each acetaminophen concentration tested are shown in the table below.

<table><tr><td colspan="1" rowspan="1">Substanceconcentration Tested</td><td colspan="1" rowspan="1">Highest Tested Concentrationwith No SignificantInterference</td><td colspan="1" rowspan="1">AcetaminophenConcentration</td></tr><tr><td colspan="1" rowspan="4">Hemoglobin(0 - 1000 mg/dL)</td><td colspan="1" rowspan="1">200 mg/dL (31μmol/L)</td><td colspan="1" rowspan="1">30 μmol/L (4.5 μg/mL)</td></tr><tr><td colspan="1" rowspan="1">200 mg/dL (31μmol/L)</td><td colspan="1" rowspan="1">93 μmol/L (14.0 μg/mL)</td></tr><tr><td colspan="1" rowspan="1">400 mg/dL (62 μmol/L)</td><td colspan="1" rowspan="1">188μmol/L (28.4 µg/mL)</td></tr><tr><td colspan="1" rowspan="1">1000 mg/dL (155 μmol/L)</td><td colspan="1" rowspan="1">861μmol/L (130 μg/mL)</td></tr><tr><td colspan="1" rowspan="5">Conjugated Bilirubin(0 - 40 mg/dL)</td><td colspan="1" rowspan="1">2 mg/dL (23.7μmol/L)</td><td colspan="1" rowspan="1">31µmol/L (4.7 μg/mL)</td></tr><tr><td colspan="1" rowspan="1">2 mg/dL (23.7μmol/L)</td><td colspan="1" rowspan="1">98 μmol/L (14.8 µg/mL)</td></tr><tr><td colspan="1" rowspan="1">32 mg/dL (364μmol/L)</td><td colspan="1" rowspan="1">115μmol/L (17.4 µg/mL)</td></tr><tr><td colspan="1" rowspan="1">40 mg/dL (475μmol/L)</td><td colspan="1" rowspan="1">200µmol/L (30.2 µg/mL)</td></tr><tr><td colspan="1" rowspan="1">40 mg/dL (475μmol/L)</td><td colspan="1" rowspan="1">957μmol/L (144 µg/mL)</td></tr><tr><td colspan="1" rowspan="5">Unconjugated Bilirubin(0 - 40 mg/dL)</td><td colspan="1" rowspan="1">2 mg/dL (34.2 μmol/L)</td><td colspan="1" rowspan="1">33 µmol/L (5.0 µg/mL)</td></tr><tr><td colspan="1" rowspan="1">4 mg/dL (68 µmol/L)</td><td colspan="1" rowspan="1">983 μmol/L (14.8 μg/mL)</td></tr><tr><td colspan="1" rowspan="1">32 mg/dL (547μmol/L)</td><td colspan="1" rowspan="1">115μmol/L (17.4 µg/mL)</td></tr><tr><td colspan="1" rowspan="1">24 mg/dL (410μmol/L)</td><td colspan="1" rowspan="1">200μmol/L (30.2 μg/mL)</td></tr><tr><td colspan="1" rowspan="1">40 mg/dL (475μmol/L)</td><td colspan="1" rowspan="1">958μmol/L (144 µg/mL)</td></tr><tr><td colspan="1" rowspan="4">Ascorbic Acid(0 - 3000 μg/dL)</td><td colspan="1" rowspan="1">3000μg/dL (170μmol/L)</td><td colspan="1" rowspan="1">30 μmol/L (4.5 μg/mL)</td></tr><tr><td colspan="1" rowspan="1">3000μg/dL (170μmol/L)</td><td colspan="1" rowspan="1">107μmol/L (16.2 μg/mL)</td></tr><tr><td colspan="1" rowspan="1">3000μg/dL (170μmol/L)</td><td colspan="1" rowspan="1">215μmol/L (32.5 µg/mL)</td></tr><tr><td colspan="1" rowspan="1">3000μg/dL (170μmol/L)</td><td colspan="1" rowspan="1">946 µmol/L (142.8 µg/mL)</td></tr><tr><td colspan="1" rowspan="4">N-Acetylcysteine(0 - 2500 mg/L)</td><td colspan="1" rowspan="1">1500 mg/L</td><td colspan="1" rowspan="1">30 μmol/L (4.5 µg/mL)</td></tr><tr><td colspan="1" rowspan="1">1500 mg/L</td><td colspan="1" rowspan="1">110 μmol/L (16.6 μg/mL)</td></tr><tr><td colspan="1" rowspan="1">1500 mg/L</td><td colspan="1" rowspan="1">215 μmol/L (32.5 µg/mL)</td></tr><tr><td colspan="1" rowspan="1">1500 mg/L</td><td colspan="1" rowspan="1">922 µmol/L (139.2 µg/mL)</td></tr><tr><td colspan="1" rowspan="2">Intralipid(0 - 1000 mg/dL)</td><td colspan="1" rowspan="1">600 mg/dL [1800 mg/dL (20mmol/L) SimulatedTriglycerides</td><td colspan="1" rowspan="1">32 μmol/L (4.8 µg/mL)</td></tr><tr><td colspan="1" rowspan="1">1000 mg/dL [3000 mg/dL(34 mmol/L) Simulated</td><td colspan="1" rowspan="1">100 µmol/L (15.1 µg/mL)</td></tr><tr><td colspan="1" rowspan="3"></td><td colspan="1" rowspan="1">Triglycerides]</td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">1000 mg/dL [3000 mg/dL(34 mmol/L) SimulatedTriglycerides]</td><td colspan="1" rowspan="1">203 μmol/L (30.7 µg/mL)</td></tr><tr><td colspan="1" rowspan="1">1000 mg/dL [3000 mg/dL(34 mmol/L) SimulatedTriglycerides]</td><td colspan="1" rowspan="1">898 µmol/L (135.6 µg/mL)</td></tr></table>

Interference from common drugs was also examined. A total of 15 commonly used drugs were examined for potential interferences. Testing was performed with serum sample pools at four levels of acetaminophen (33, 100, 199, and $9 0 0 \mu \mathrm { m o l / L } )$ . Recoveries of acetaminophen were within the sponsor’s acceptance criteria of greater than $\pm 1 0 \%$ or $8 ~ \mu \mathrm { m o l / L }$ from control. The highest concentrations of common drugs shown not to interfere with the assay are provided in the table below.

<table><tr><td rowspan=1 colspan=1>Substance Tested</td><td rowspan=1 colspan=1>Concentration with No SignificantInterference</td></tr><tr><td rowspan=1 colspan=1>Theophylline</td><td rowspan=1 colspan=1>222 μmol/L</td></tr><tr><td rowspan=1 colspan=1>Phenylbutazone</td><td rowspan=1 colspan=1>2.89 mmol/L</td></tr><tr><td rowspan=1 colspan=1>Ibuprofen</td><td rowspan=1 colspan=1>2425 μmol/L</td></tr><tr><td rowspan=1 colspan=1>Imipramine</td><td rowspan=1 colspan=1>2.5 μmol/L</td></tr><tr><td rowspan=1 colspan=1>Acetylsalicylic Acid</td><td rowspan=1 colspan=1>6.51 mmol/L</td></tr><tr><td rowspan=1 colspan=1>Levodopa</td><td rowspan=1 colspan=1>25.3 μmol/L</td></tr><tr><td rowspan=1 colspan=1>Ampicillin</td><td rowspan=1 colspan=1>152 μmol/L</td></tr><tr><td rowspan=1 colspan=1>Doxycycline</td><td rowspan=1 colspan=1>67.5 μmol/L</td></tr><tr><td rowspan=1 colspan=1>Amitriptyline</td><td rowspan=1 colspan=1>3.61 μmol/L</td></tr><tr><td rowspan=1 colspan=1>Metronidazole</td><td rowspan=1 colspan=1>701 μmol/L</td></tr><tr><td rowspan=1 colspan=1>Cefoxitin</td><td rowspan=1 colspan=1>1546 μmol/L</td></tr><tr><td rowspan=1 colspan=1>Cyclosporine</td><td rowspan=1 colspan=1>10.0 μmol/L</td></tr><tr><td rowspan=1 colspan=1>Methyldopa</td><td rowspan=1 colspan=1>71 μmol/L</td></tr><tr><td rowspan=1 colspan=1>Rifampicin</td><td rowspan=1 colspan=1>78.1 μmol/L</td></tr><tr><td rowspan=1 colspan=1>Salicylate</td><td rowspan=1 colspan=1>4.34 mmol/L</td></tr></table>

f. Assay cut-off:

Not applicable.

# a. Method comparison with predicate device:

A method comparison test was conducted on the Roche Hitachi 717 analyzer using three lots of SEKURE Acetaminophen L3K reagent, as compared to one lot of the predicate Acetaminophen L3K reagent. 105 samples were tested in singlicate. The samples tested ranged from 116 to $2 4 4 7 \ \mathrm { \mu m o l / L }$ b $( 1 7 . 5 - 3 6 9 . 4 \mu \mathrm { g / m L } )$ ). Deming regression analysis resulted in a slope of 0.974, a y-intercept of $4 . 7 \mu \mathrm { m o l / L }$ , and a correlation coefficient of 0.9999. Passing-Bablok regression analysis resulted in a slope of 0.975, a y-intercept of $2 . 3 \ \mu \mathrm { m o l / L }$ , and a correlation coefficient of 0.9999.

# b. Matrix comparison:

Matrix comparison studies were performed for Serum (with gel in plastic, SST), EDTA, Lithium heparin (with gel in plastic, PST), Lithium heparin (without gel in plastic), Lithium heparin (Barricor tube), Sodium heparin (without gel in plastic) vs serum (without gel in plastic). A set of fifty matched sample sets were tested and percent recovery was determined. All percent recoveries were within $\pm 1 0 \%$ .

<table><tr><td rowspan=2 colspan=1></td><td rowspan=2 colspan=1>SampleRange</td><td rowspan=1 colspan=2>Slope</td><td rowspan=1 colspan=1>Correlation Coefficient</td></tr><tr><td rowspan=1 colspan=1>Result Deming</td><td rowspan=1 colspan=1>Passing-Bablok</td><td rowspan=1 colspan=1>Result</td></tr><tr><td rowspan=1 colspan=1>SST</td><td rowspan=4 colspan=1>115  2322μmol/L</td><td rowspan=1 colspan=1>1.012</td><td rowspan=1 colspan=1>1.007</td><td rowspan=1 colspan=1>1.000</td></tr><tr><td rowspan=1 colspan=1>EDTA</td><td rowspan=1 colspan=1>0.303</td><td rowspan=1 colspan=1>0.303</td><td rowspan=1 colspan=1>0.988</td></tr><tr><td rowspan=1 colspan=1>LithiumHeparin</td><td rowspan=1 colspan=1>1.015</td><td rowspan=1 colspan=1>1.012</td><td rowspan=1 colspan=1>1.000</td></tr><tr><td rowspan=1 colspan=1>PST</td><td rowspan=1 colspan=1>1.009</td><td rowspan=1 colspan=1>1.000</td><td rowspan=1 colspan=1>1.000</td></tr><tr><td rowspan=1 colspan=1>SodiumHeparin</td><td rowspan=2 colspan=1></td><td rowspan=1 colspan=1>1.012</td><td rowspan=1 colspan=1>1.006</td><td rowspan=1 colspan=1>1.000</td></tr><tr><td rowspan=1 colspan=1>Barricor</td><td rowspan=1 colspan=1>1.005</td><td rowspan=1 colspan=1>1.000</td><td rowspan=1 colspan=1>1.000</td></tr></table>

3. Clinical studies:

a. Clinical Sensitivity:   
Not applicable.   
b. Clinical specificity:   
Not applicable.

c. Other clinical supportive data (when a. and b. are not applicable): Not applicable.

4. Clinical cut-off: Not applicable.

5. Expected values/Reference range:

Reference range were cited from the following literatures: Tietz Textbook of Clinical Chemistry, Second Edition, pp 1168, 2212, W.B. Saunders Company, Philadelphia (1994)

Therapeutic concentration: $1 0 { - } 3 0 ~ \mu \mathrm { g / m L }$ $( 6 6 { - } 1 9 9 \ \mu \mathrm { m o l / L } )$ Toxic concentration: $> 2 0 0 ~ \mu \mathrm { g / m L }$ $( 1 3 2 4 \mu \mathrm { m o l / L } )$

These values are suggested guidelines. It is recommended that each laboratory establish its own expected range.

# N. Proposed Labeling:

The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

# O. Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.